Skip to main content
LGND
NASDAQ Life Sciences

Ligand Pharmaceuticals Reports Strong Q4 & Full Year 2025 Results, Exceeding EPS Guidance by 30% and Reaffirming 2026 Outlook

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$191.5
Mkt Cap
$3.767B
52W Low
$93.58
52W High
$212.49
52W Position info
105% above low
Off High info
9.9% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

LGND has more than doubled off its 52-week low of $93.58.

Summary

Ligand Pharmaceuticals announced robust fourth quarter and full year 2025 financial results, significantly exceeding its initial full-year adjusted EPS guidance by approximately 30%, driven by strong royalty revenue growth and positive pipeline advancements. The company also reaffirmed its 2026 financial guidance.


Key Events · Earnings and Guidance · LGND

  • Strong Financial Performance

    Reported Q4 2025 total revenues of $59.7 million (+39% YoY) and full year 2025 total revenues of $268.1 million (+60% YoY).

  • Significant EPS Beat

    Full year 2025 adjusted EPS of $8.13 exceeded initial guidance by approximately 30%, a substantial improvement from a GAAP net loss in 2024.

  • Robust Royalty Revenue Growth

    Full year 2025 royalty revenue grew 48% to $161.0 million, driven by increased sales of key products like Filspari, Capvaxive, and Ohtuvayre.

  • 2026 Guidance Reaffirmed

    The company reiterated its 2026 financial guidance, projecting total revenues of $245-$285 million and adjusted EPS of $8.00-$9.00, demonstrating confidence in future performance.


Analysis · LGND · Life Sciences

This 8-K reports highly positive financial performance for Ligand Pharmaceuticals, with the company achieving a substantial turnaround from a GAAP net loss in 2024 to significant profitability in 2025. The reported full-year 2025 adjusted EPS of $8.13 notably surpassed initial guidance by approximately 30%, indicating strong operational execution and better-than-expected performance across its royalty portfolio. The reaffirmation of 2026 financial guidance, including projected revenues of $245-$285 million and adjusted EPS of $8.00-$9.00, signals management's confidence in sustained growth. Additionally, the filing highlights multiple positive developments in key partnered programs, such as a successful Phase 3 trial for Qtorin rapamycin and expedited FDA review for Tzield, further strengthening the company's long-term value proposition.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LGND was trading at $191.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $93.58 to $212.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LGND - Latest Insights

LGND
Oct 30, 2026, 4:47 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $324.00
Real-time Price: $315.98 info
Change: -$8.02 (-2%) info
Market Cap: $6.326B info
LGND
Oct 29, 2026, 3:12 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $316.21
Real-time Price: $315.98 info
Change: -$0.230 (-0.07%) info
Market Cap: $6.326B info
LGND
Oct 29, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $311.87
Real-time Price: $315.98 info
Change: +$4.11 (+1%) info
Market Cap: $6.326B info
LGND
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $311.87
Real-time Price: $315.98 info
Change: +$4.11 (+1%) info
Market Cap: $6.326B info
LGND
Sep 24, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $298.41
Real-time Price: $315.98 info
Change: +$17.57 (+6%) info
Market Cap: $6.326B info